Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Efficacy and Safety Study of Ataluren in Nonsense Mutation Cystic Fibrosis
2013-004581-34Phase 3Completed
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cystic fibrosis (CF) comparing Ataluren with Placebo (2 arms). Primary endpoint: Change in FEV1. Started Jun 2014; status: completed.
02
Drugs
ataluren
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2013-004581-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004581-34.